Furthermore, administration of sevelamer as a calcium-free phosphate binder to lower phosphate has also proven to be good for control of serum PTH and FGF-23 levels (Six et al., 2020), and hence would slow the progression of vascular calcification in CKD. Here, FGF23 is linked to chronic kidney disease.